Frederick F. Lang

OverviewAI-generated summary

Frederick F. Lang's research focuses on cancer treatment outcomes, particularly in the context of neurological and oncological conditions. He has investigated the impact of immune checkpoint inhibitors on survival and central nervous system progression in non-small cell lung cancer patients with brain metastases, as detailed in a 2026 systematic review and meta-analysis. Lang's work also includes studies on glioblastoma, examining oncogenic drivers' influence on the tumor microenvironment and molecular determinants of response to immunotherapy. He has been involved in clinical trials, including a phase 1/2 trial of oncolytic virotherapy combined with pembrolizumab for recurrent glioblastoma.

Further research areas include the treatment of chronic subdural hematoma in cancer patients, comparing middle meningeal artery embolization with surgical drainage. Lang is also the PI on a $76,500 NIH/National Cancer Institute grant for the development of immunocompetent melanoma brain metastases organoids. His scholarship metrics include an h-index of 6 and 1,057 total citations across 15 publications. He has collaborated with researchers at the University of Arkansas for Medical Sciences, including William J. Shelton and A Mathews, with whom he shares one publication each.

Metrics

• h-index: 6
• Publications: 15
• Citations: 1,057